{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:09:52Z","timestamp":1775466592692,"version":"3.50.1"},"posted":{"date-parts":[[2026,4,2]]},"group-title":"Endocrinology (including Diabetes Mellitus and Metabolic Disease)","reference-count":44,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Wolfram syndrome is a rare autosomal recessive disorder caused by pathogenic variants in the\n                  <jats:italic>WFS1<\/jats:italic>\n                  gene, characterized by early-onset diabetes mellitus, optic atrophy, sensorineural hearing loss, arginine vasopressin deficiency, and progressive neurodegeneration. The condition selectively affects pancreatic \u03b2 cells and neurons via chronic endoplasmic reticulum (ER) stress, and no proven disease-modifying therapy currently exists. Diabetes mellitus is typically the first manifestation, presenting at a mean age of 6 years as an insulin-dependent phenotype with preserved C-peptide and negative diabetes-related autoantibodies.\n                <\/jats:p>\n                <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well-established agents in the management of type 2 diabetes, augmenting glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety. Preclinical evidence further suggests that GLP-1 RAs preserve \u03b2-cell mass, attenuate ER stress, and confer neuroprotective effects, properties of particular therapeutic relevance to Wolfram syndrome.<\/jats:p>\n                <jats:p>We conducted a retrospective cohort study of 84 participants with genetically confirmed Wolfram syndrome and insulin-dependent diabetes mellitus enrolled in the Washington University Wolfram Syndrome International Registry and Clinical Study. Clinical data were extracted from medical records; for participants concurrently enrolled in the Tracking Neurodegeneration in Early Wolfram Syndrome study, longitudinal data were obtained from that source as well. Thirty-five percent of eligible participants had received a GLP-1 RA at some point during follow-up. We characterize the prevalence of GLP-1 RA use, documented rationale for initiation, observed effects on glycemic control and visual outcomes, adverse effects, and reasons for discontinuation. No statistically significant changes in hemoglobin A1c (HbA1c) or body mass index (BMI) were observed. Visual acuity declined significantly at two years, consistent with expected disease progression. Gastrointestinal adverse effects were common and contributed to frequent discontinuation.<\/jats:p>\n                <jats:p>These observational data provide important clinical context and a foundation for future prospective trials evaluating GLP-1 RAs as a potential disease-modifying strategy in Wolfram syndrome.<\/jats:p>","DOI":"10.64898\/2026.03.31.26349885","type":"posted-content","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:10:17Z","timestamp":1775153417000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Use of GLP-1 Receptor Agonists in Wolfram syndrome Patients"],"prefix":"10.64898","author":[{"given":"Laura","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby F.","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Asako","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah F.","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayden A.","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Duncan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather M.","family":"Lugar","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Hoekel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bess A.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Cell Biology, Division of Endocrinology and Diabetes, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Hershey","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"},{"name":"Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"},{"name":"Department of Radiology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9944-6293","authenticated-orcid":false,"given":"Fumihiko","family":"Urano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"},{"name":"Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2026040601300634000_2026.03.31.26349885v1.1","doi-asserted-by":"crossref","unstructured":"Abreu, D. , and Urano, F . (2019). Current Landscape of Treatments for Wolfram Syndrome. Trends Pharmacol Sci.","DOI":"10.1016\/j.tips.2019.07.011"},{"key":"2026040601300634000_2026.03.31.26349885v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92473-6"},{"key":"2026040601300634000_2026.03.31.26349885v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.09.003"},{"key":"2026040601300634000_2026.03.31.26349885v1.4","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S348055"},{"key":"2026040601300634000_2026.03.31.26349885v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"2026040601300634000_2026.03.31.26349885v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr2409089"},{"key":"2026040601300634000_2026.03.31.26349885v1.7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2026040601300634000_2026.03.31.26349885v1.8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-025-04124-5","article-title":"The expanding landscape of GLP-1 medicines","volume":"32","year":"2026","journal-title":"Nat Med"},{"key":"2026040601300634000_2026.03.31.26349885v1.9","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M507426200"},{"key":"2026040601300634000_2026.03.31.26349885v1.10","doi-asserted-by":"publisher","DOI":"10.1172\/Jci39678"},{"key":"2026040601300634000_2026.03.31.26349885v1.11","doi-asserted-by":"crossref","first-page":"755365","DOI":"10.3389\/fped.2021.755365","article-title":"Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients","volume":"9","year":"2021","journal-title":"Front Pediatr"},{"key":"2026040601300634000_2026.03.31.26349885v1.12","doi-asserted-by":"crossref","first-page":"1675552","DOI":"10.3389\/fphar.2025.1675552","article-title":"GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy","volume":"16","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026040601300634000_2026.03.31.26349885v1.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05905-8"},{"key":"2026040601300634000_2026.03.31.26349885v1.14","doi-asserted-by":"crossref","unstructured":"Gorgojo-Martinez, J.J. , Mezquita-Raya, P. , Carretero-Gomez, J. , Castro, A. , Cebrian-Cuenca, A. , De Torres-Sanchez, A. , Garcia-De-Lucas, M.D. , Nunez, J. , Obaya, J.C. , Soler, M.J. , Gorriz, J.L. , and Rubio-Herrera, M.A. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med 12.","DOI":"10.3390\/jcm12010145"},{"key":"2026040601300634000_2026.03.31.26349885v1.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040604"},{"key":"2026040601300634000_2026.03.31.26349885v1.16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaapos.2014.07.162","article-title":"Ophthalmologic correlates of disease severity in children and adolescents with Wolfram syndrome","volume":"18","author":"Washington University Wolfram Study, G.","year":"2014","journal-title":"J AAPOS"},{"key":"2026040601300634000_2026.03.31.26349885v1.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2017-000081"},{"key":"2026040601300634000_2026.03.31.26349885v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/2441"},{"key":"2026040601300634000_2026.03.31.26349885v1.19","doi-asserted-by":"crossref","unstructured":"Jagomae, T. , Seppa, K. , Reimets, R. , Pastak, M. , Plaas, M. , Hickey, M.A. , Kukker, K.G. , Moons, L. , De Groef, L. , Vasar, E. , Kaasik, A. , Terasmaa, A. , and Plaas, M. (2021). Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype. Cells 10.","DOI":"10.21203\/rs.3.rs-903256\/v1"},{"key":"2026040601300634000_2026.03.31.26349885v1.20","doi-asserted-by":"crossref","unstructured":"Jalleh, R.J. , Talley, N.J. , Horowitz, M. , and Nauck, M.A . (2026). The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. J Clin Invest 136.","DOI":"10.1172\/JCI194740"},{"key":"2026040601300634000_2026.03.31.26349885v1.21","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.12.1566"},{"key":"2026040601300634000_2026.03.31.26349885v1.22","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00125-018-4679-y","article-title":"Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome","volume":"61","year":"2018","journal-title":"Diabetologia"},{"key":"2026040601300634000_2026.03.31.26349885v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106550"},{"key":"2026040601300634000_2026.03.31.26349885v1.24","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1198171"},{"key":"2026040601300634000_2026.03.31.26349885v1.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1421055111"},{"key":"2026040601300634000_2026.03.31.26349885v1.26","doi-asserted-by":"crossref","unstructured":"Mcneely, B.J. , Tang, A.F. , Urano, F. , Levergood, N.R. , Ko, M.W. , Mackay, D.D. , Van Stavern, G.P. , and Tang, Y. (2026). Optic Atrophy in Wolfram Syndrome Type 1: A Retrospective Analysis of Visual Outcomes and Biomarker Correlates. J Neuroophthalmol.","DOI":"10.1097\/WNO.0000000000002451"},{"key":"2026040601300634000_2026.03.31.26349885v1.27","first-page":"26330040211039518","article-title":"Wolfram syndrome: new pathophysiological insights and therapeutic strategies","volume":"2","year":"2021","journal-title":"Ther Adv Rare Dis"},{"key":"2026040601300634000_2026.03.31.26349885v1.28","doi-asserted-by":"crossref","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026040601300634000_2026.03.31.26349885v1.29","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305745"},{"key":"2026040601300634000_2026.03.31.26349885v1.30","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","year":"2021","journal-title":"Mol Metab"},{"key":"2026040601300634000_2026.03.31.26349885v1.31","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","year":"2026","journal-title":"Lancet"},{"key":"2026040601300634000_2026.03.31.26349885v1.32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajo.2022.07.003","article-title":"Longitudinal Changes in Vision and Retinal Morphology in Wolfram Syndrome","volume":"243","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"2026040601300634000_2026.03.31.26349885v1.33","doi-asserted-by":"crossref","first-page":"1171091","DOI":"10.3389\/fcdhc.2023.1171091","article-title":"GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder","volume":"4","year":"2023","journal-title":"Front Clin Diabetes Healthc"},{"key":"2026040601300634000_2026.03.31.26349885v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14571-0"},{"key":"2026040601300634000_2026.03.31.26349885v1.35","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8644"},{"key":"2026040601300634000_2026.03.31.26349885v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09392-x"},{"key":"2026040601300634000_2026.03.31.26349885v1.37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/pedi.13291","article-title":"Longitudinal progression of diabetes mellitus in Wolfram syndrome: The Washington University Wolfram Research Clinic experience","volume":"23","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2026040601300634000_2026.03.31.26349885v1.38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349"},{"key":"2026040601300634000_2026.03.31.26349885v1.39","doi-asserted-by":"crossref","first-page":"15742","DOI":"10.1038\/s41598-019-52295-2","article-title":"GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome","volume":"9","year":"2019","journal-title":"Sci Rep"},{"key":"2026040601300634000_2026.03.31.26349885v1.40","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0717"},{"key":"2026040601300634000_2026.03.31.26349885v1.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28314-z"},{"key":"2026040601300634000_2026.03.31.26349885v1.42","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-015-0702-6"},{"key":"2026040601300634000_2026.03.31.26349885v1.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"2026040601300634000_2026.03.31.26349885v1.44","doi-asserted-by":"crossref","first-page":"694613","DOI":"10.1155\/2013\/694613","article-title":"Prospective study on retinal nerve fibre layer thickness changes in isolated unilateral retrobulbar optic neuritis","volume":"2013","year":"2013","journal-title":"ScientificWorldJournal"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.03.31.26349885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T08:30:19Z","timestamp":1775464219000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.03.31.26349885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":44,"URL":"https:\/\/doi.org\/10.64898\/2026.03.31.26349885","relation":{},"subject":[],"published":{"date-parts":[[2026,4,2]]},"subtype":"preprint"}}